serolog
test
crucial
tool
assess
exposur
infect
potenti
immun
appropri
use
interpret
requir
accur
assay
perform
data
conduct
evalu
later
flow
assay
lfa
two
elisa
detect
antibodi
specimen
set
compris
plasma
serum
sampl
symptomat
rtpcrposit
individu
neg
control
recent
sampl
individu
underw
respiratori
viral
test
diagnos
coronaviru
diseas
sampl
blind
lfa
result
interpret
two
independ
reader
use
standard
intens
score
system
among
specimen
rtpcrposit
individu
percent
seroposit
increas
time
interv
peak
sampl
taken
day
symptom
onset
test
specif
rang
specimen
specif
higher
weak
lfa
band
consid
neg
decreas
sensit
igm
detect
variabl
igg
detect
highest
igm
igg
result
combin
agreement
elisa
lfa
rang
consist
crossreact
observ
evalu
show
heterogen
assay
perform
reader
train
key
reliabl
lfa
perform
tailor
survey
goal
inform
use
serolog
requir
evalu
cover
full
spectrum
infect
asymptomat
mild
infect
sever
diseas
later
convalesc
welldesign
studi
elucid
mechan
serolog
correl
protect
immun
crucial
guid
ration
clinic
public
health
polici
april
death
attribut
coronaviru
diseas
million
infect
viru
respons
report
though
full
extent
yet
determin
due
limit
test
govern
intervent
slow
viral
spread
disrupt
daili
life
econom
activ
billion
peopl
strategi
eas
restraint
human
mobil
interact
without
provok
major
resurg
transmiss
mortal
depend
accur
estim
popul
level
infect
immun
current
test
viru
larg
depend
laborintens
molecular
techniqu
individu
posit
molecular
test
repres
small
fraction
infect
given
limit
deploy
brief
time
window
pcr
test
sensit
proport
undetect
case
origin
epidem
focu
estim
high
asymptomat
infect
suspect
play
substanti
role
transmiss
wide
avail
reliabl
antibodi
detect
assay
would
enabl
accur
estim
preval
incid
februari
secretari
unit
state
depart
health
human
servic
issu
emerg
use
author
eua
diagnosi
allow
nucleic
acid
detect
immunoassay
test
offer
base
manufacturerreport
data
without
formal
fda
clearanc
respons
dozen
compani
begun
market
laboratorybas
immunoassay
pointofcar
test
rigor
compar
perform
data
crucial
inform
clinic
care
public
health
respons
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
conduct
headtohead
comparison
avail
serolog
test
immunochromatograph
later
flow
assay
lfa
enzymelink
immunosorb
assay
elisa
includ
evalu
perform
time
symptom
onset
diseas
sever
goal
provid
wellcontrol
perform
data
highlight
potenti
use
serolog
assay
help
guid
develop
deploy
ethic
approv
studi
approv
institut
review
board
univers
individu
one
sampl
per
time
interv
day
symptom
onset
individu
one
specimen
given
time
interv
later
specimen
includ
specif
includ
specimen
american
red
cross
blood
donor
assess
crossreact
use
specimen
test
result
respiratori
virus
biofir
filmarray
biofir
diagnost
salt
lake
citi
ut
individu
neg
result
rtpcr
base
minimum
sampl
size
calcul
expect
binomi
exact
confid
limit
total
sampl
includ
final
analysi
includ
rtpcrposit
individu
specimen
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
exhaust
analysi
includ
test
data
obtain
sampl
conform
studi
design
exclud
clinic
data
extract
electron
health
record
enter
hipaasecur
redcap
databas
host
ucsf
data
includ
demograph
inform
major
comorbid
patientreport
symptom
onset
date
symptom
indic
sever
independ
data
test
effort
mgh
slight
deviat
method
includ
supplementari
data
briefli
heatinactiv
serumplasma
sampl
rtpcrposit
individu
includ
specif
mgh
studi
includ
heatinactiv
sampl
asymptomat
adult
individu
admit
febril
andor
respiratori
ill
confirm
pathogen
sampl
prepar
sampl
ucsf
zsfg
assign
random
well
posit
one
four
plate
sampl
thaw
transfer
assign
well
without
heat
inactiv
sampl
subaliquot
replica
plate
test
replica
plate
store
need
thaw
ten
minut
room
temperatur
briefli
centrifug
test
sampl
handl
follow
ucsf
biosafeti
committeeapprov
biosafeti
level
practic
mgh
studi
sampl
heatinactiv
minut
aliquot
store
sampl
store
use
within
day
frozen
aliquot
store
need
singl
freezethaw
cycl
sampl
sampl
brought
room
temperatur
briefli
centrifug
prior
ad
recommend
volum
lfa
cartridg
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
immunochromatograph
later
flow
assay
lfa
ten
later
flow
assay
evalu
sampl
ucsf
zsfg
supplementari
tabl
time
test
cartridg
label
random
sampl
locat
plate
well
appropri
sampl
volum
transfer
plate
indic
sampl
port
follow
immedi
provid
diluent
follow
manufactur
instruct
later
flow
cartridg
incub
recommend
time
room
temperatur
read
cartridg
assign
semiquantit
score
neg
posit
test
line
intens
two
independ
reader
blind
specimen
statu
score
supplementari
figur
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
valu
distribut
plasma
elisa
backgroundcorrect
od
valu
divid
cutoff
gener
signaltocutoff
sco
ratio
sampl
sco
valu
greater
consid
posit
data
analysi
lfa
test
second
reader
score
use
perform
calcul
first
reader
score
use
calcul
interread
agreement
statist
percent
seroposit
among
rtpcrconfirm
case
calcul
time
interv
symptom
onset
specif
base
result
sampl
binomi
exact
confid
interv
calcul
estim
analys
conduct
r
sa
studi
popul
individu
ucsfzsfg
studi
rang
year
age
figur
reach
highest
level
day
time
interv
highest
detect
rate
achiev
combin
igm
igg
result
figur
howev
confid
interv
later
time
interv
show
substanti
overlap
earlier
interv
figur
four
assay
bioperfectu
premier
wondfo
inhous
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
elisa
achiev
posit
latest
two
time
interv
day
maintain
specif
test
perform
subset
specimen
due
exhaust
sampl
materi
may
affect
report
percent
posit
igm
detect
less
consist
igg
nearli
assay
kappa
agreement
statist
rang
igg
igm
standard
intens
score
train
supplementari
tabl
supplementari
figur
although
variabl
mean
band
intens
exist
among
differ
assay
rate
sampl
posit
gener
consist
figur
observ
trend
toward
higher
percent
posit
lfa
patient
admit
icu
compar
milder
diseas
specimen
number
per
time
interv
low
limit
statist
power
supplementari
figur
test
specif
rang
sampl
demonstr
fals
posit
result
least
one
lfa
tabl
figur
fals
posit
result
weak
posit
score
intens
score
seen
score
seen
posit
sampl
evalu
tradeoff
percent
posit
specif
function
lfa
reader
score
chang
posit
lfa
threshold
decreas
mean
overal
percent
posit
across
test
rang
rang
increas
averag
specif
rang
rang
supplementari
figur
independ
studi
mgh
compar
three
lfa
biomedom
also
assess
current
studi
supplementari
tabl
overal
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
agreement
result
lfa
igg
igm
epitop
elisa
rang
agreement
inhous
elisa
rang
figur
lfa
band
intens
score
show
direct
correl
elisa
sco
valu
figur
studi
describ
test
perform
serolog
assay
panel
sampl
individu
pcrconfirm
infect
specimen
test
quantifi
detect
igm
andor
igg
antibodi
time
period
onset
symptom
assess
specif
crossreact
hope
data
inform
medic
commun
public
health
effort
government
institut
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
plan
serolog
test
studi
also
seek
provid
feedback
manufactur
area
success
necessari
improv
gold
standard
identifi
true
seroposit
blood
sampl
extent
timecours
antibodi
develop
fulli
understood
yet
may
vari
differ
popul
even
among
rtpcrconfirm
case
focus
comparison
percent
posit
time
interv
rather
report
sensit
assay
expect
percent
posit
rose
time
symptom
onset
high
rate
posit
result
reach
least
week
clinic
ill
diagnosi
time
symptom
onset
thu
remain
depend
viral
detect
method
assay
show
trend
higher
posit
rate
within
time
interv
sever
diseas
find
interpret
caution
due
limit
data
ambulatori
case
major
sampl
day
postsymptom
onset
detect
antibodi
suggest
good
excel
sensit
evalu
test
hospit
patient
three
week
diseas
cours
howev
wellpow
studi
test
ambulatori
asymptomat
individu
includ
perform
capillari
blood
essenti
guid
appropri
use
serolog
data
demonstr
specif
greater
major
test
evalu
lfa
wondfo
sure
biotech
inhous
elisa
adapt
amanat
et
al
observ
moderatetostrong
posit
band
sever
blood
donor
specimen
posit
multipl
assay
suggest
possibl
nonspecif
bind
plasma
protein
nonspecif
antibodi
crossreact
virus
three
specimen
score
posit
three
assay
intriguingli
fraction
posit
test
higher
set
recent
specimen
obtain
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
outbreak
individu
undergo
respiratori
viral
workup
mani
neg
rtpcr
five
posit
result
three
assay
without
relat
specif
viral
pathogen
suggest
nonspecif
reactiv
andor
miss
diagnos
one
specimen
posit
assay
includ
inhous
elisa
patient
year
old
present
alter
mental
statu
fever
high
specif
test
crucial
lowpreval
set
one
approach
increas
specif
would
employ
confirmatori
test
independ
assay
perhap
recogn
distinct
epitop
antigen
comparison
ucsf
mgh
data
suggest
reclassifi
faint
band
neg
inconclus
would
increas
specif
albeit
expens
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
sensit
detect
cutoff
select
recogn
like
tradeoff
specif
sensit
popul
preval
goal
test
accur
lfa
use
also
depend
adequ
reader
train
standard
intens
cutoff
find
highlight
need
rigor
evalu
altern
implement
algorithm
multipl
set
studi
also
reinforc
need
assay
valid
use
standard
sampl
set
known
posit
individu
rang
clinic
present
multipl
time
point
onset
symptom
outbreak
sampl
specif
sampl
individu
viral
inflammatori
ill
crossreact
control
coordin
effort
valid
ensur
widespread
avail
standard
sampl
set
would
facilit
effect
util
continu
evalu
serolog
assay
provid
updat
data
dedic
websit
http
covidtestingprojectorg
current
futur
studi
group
other
provid
essenti
evid
base
guid
serolog
test
pandem
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
immun
compromis
condit
includ
rheumatolog
patient
rheumatoid
arthriti
psoriasi
crohn
diseas
ankylos
spondyl
reactiv
arthriti
take
immun
modulatingsuppress
therapi
ambulatori
care
includ
outpati
well
patient
seen
ed
admit
tabl
baselin
demograph
characterist
present
symptom
chronic
medic
condit
initi
disposit
highestlevel
outcom
particip
whose
sampl
includ
time
interv
serolog
test
one
sampl
per
patient
includ
time
interv
individu
repres
multipl
sampl
differ
time
interv
total
test
sampl
taken
rtpcrposit
case
patient
solid
organ
transplant
cad
asthma
chf
liver
diseas
malign
emphysema
prior
stroke
hiv
immun
compromis
condit
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
tabl
summari
statist
immunochromatograph
later
flow
assay
lfa
enzymelink
immunosorb
assay
elisa
sampl
bin
time
patientreport
symptom
onset
rtpcrposit
case
percent
seroposit
assess
assay
rtpcrposit
sampl
report
confid
interv
ci
column
igm
igg
refer
posit
either
isotyp
specif
determin
rel
neg
control
serum
sampl
percent
seroposit
assess
assay
report
confid
interv
sampl
individu
posit
viral
infect
andor
test
neg
rtpcr
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
data
plot
igm
igg
depend
elisa
comparison
f
ab
specif
secondari
antibodi
use
inhous
elisa
preferenti
bind
igg
light
chain
contain
reactiv
isotyp
igm
iga
error
bar
signifi
confid
interv
